02171.HK
CARsgen Therapeutics Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 12.75
+3.66%Year over year
Reported trailing growth
- Revenue
- +62.6%
- EBITDA
- +30.7%
- EBIT
- +81.1%
- EPS
- +83.8%
- Free cash flow
- +85.0%
- Operating cash flow
- +86.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +218.7%
- EBITDA
- +59.0%
- EBIT
- +87.1%
- Net income
- +87.7%
- EPS
- +87.5%
- Free cash flow
- +43.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026